
Novan, Inc.
Novan, Inc. (NOVN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
novn · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Novan, Inc.You NOVN | $3M | N/A | — | — |
Affimed N.V. AFMD | $3M | N/A | — | -$7.09 |
Aravive, Inc. ARAV | $3M | N/A | — | -$2.22 |
Biophytis S.A. BPTS | $3M | N/A | — | -$12.55 |
Eiger BioPharmaceuticals, Inc. EIGRQ | $13M | N/A | — | -$50.78 |
Midatech Pharma plc MTP | $2M | N/A | — | -$0.00 |
Notable Labs, Ltd. NTBL | $2M | N/A | — | -$5.03 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Novan, Inc. (NOVN) measures how much investors pay for each dollar of the company's trailing earnings. NOVN's current PE ratio of N/A is calculated by dividing its stock price of $0.09 by its TTM earnings per share of —.
Frequently asked questions
NOVN pe ratio · 6 questionsNOVN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.09 and TTM EPS of —. Data sourced from Financial Modeling Prep via NOVN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Novan, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09